

Press Release

Matthias Link
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
matthias.link@fresenius.com
www.fresenius.com

March 14, 2014

Fresenius proposes three-for-one stock split

Fresenius will propose a three-for-one stock split to its Annual General Shareholder Meeting (AGM) on May 16, 2014. Under this proposal, the subscribed capital and the number of shares will be tripled. This will be accomplished by issuing new shares through the conversion of capital reserves from company funds. Every shareholder will receive two additional shares for each share held. The share price can be expected to adjust itself without affecting the overall value for shareholders.

Ulf Mark Schneider, CEO of Fresenius, said: "Our share price has more than tripled in the past 5 years and is above €100. The proposed three-for-one stock split reflects our confidence in the long-term growth prospects and financial strength of Fresenius. With the stock split, we would like to promote trading activity and increase the stock's attractiveness for a broader group of investors."

The AGM agenda will be published on April 2, 2014. In accordance with the proposed stock split, the Company also proposes to adjust the existing authorized capital and the conditional capitals as well as the authorization to buy back shares.

The subscribed capital of Fresenius SE & Co. KGaA currently amounts to €179,808,205, divided into 179,808,205 ordinary shares.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2013, Group sales were €20.3 billion. On December 31, 2013, the Fresenius Group had 178,337 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz,
Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick